|
アリムラ ケン
有村 健 所属 医学部 医学科（東京女子医科大学病院） 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. |
| 掲載誌名 | 正式名：Oncology letters 略 称：Oncol Lett ISSNコード：(1792-1074)1792-1074(Linking) |
| 掲載区分 | 国外 |
| 巻・号・頁 | 13(5),pp.3285-3290 |
| 著者・共著者 | Naoki Katsuhiko†, Takeda Yuichiro, Soejima Kenzo, Arai Daisuke, Naka Go, Nagase Seisuke, Arimura Ken, Kanemura Toshinori, Ohhira Tatsuo, Ikeda Norihiko |
| 発行年月 | 2017/05 |
| 概要 | First-line chemotherapy regimens that include bevacizumab (Bev) have been hypothesized to improve outcomes in patients with advanced non-squamous non-small cell lung cancer (non-sq NSCLC). Although approved to treat NSCLC in 2009, insufficient data exist on the clinical uses of Bev in Japan. The present study prospectively evaluated the efficacy and safety of Bev-containing combination chemotherapy. Eligible patients exhibited histologically or cytologically documented advanced or recurrent non-sq NSCLC. Patients were administered 15 mg/kg Bev with standard chemotherapy followed by maintenance Bev. The primary endpoints were progression-free survival (PFS) and safety. A total of 102 patients with non-sq NSCLC were enrolled, 44.1% of whose tumor carried epidermal growth factor receptor (EGFR) mutations. The overall response rate to the intervention was 44.1%, and the median PFS was 8.3 months [95% confidence interval (CI)=6.4-10.2 months]. The median overall survival was 26.3 months (95% CI=22.2-30.4 months). The incidence of Bev-associated severe adverse events was similar to those in previous trials, excluding a grade 3-4 hypertension rate of 30.4% in the present study. Multivariate analysis revealed that a higher TNM classification of malignant tumor staging-T factor, adjusted hazard ratio (HR)=1.33 (95% CI=1.10-1.61), and poor performance status [adjusted HR=1.63 (1.02-2.60)] were associated with significantly shorter PFS, whilst the EGFR exon 19 deletion was significantly associated with prolonged PFS [adjusted HR=0.47 (0.25-0.87)]. Bev-containing chemotherapy was safe and effective for patients with non-sq NSCLC in clinical settings in Japan. The EGFR exon 19 deletion was suggested as a positive predictive factor for the efficacy of Bev-containing chemotherapy. |
| DOI | 10.3892/ol.2017.5796 |
| PMID | 28521435 |